Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
- 1 July 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical and Translational Oncology
- Vol. 10 (7), 395-398
- https://doi.org/10.1007/s12094-008-0221-x
Abstract
Histone deacetylases (HDACs) remove the acetyl groups of lysine residues of histone tails leading to chromatin compaction and transcriptional repression. In addition, HDACs can also influence transcription-independent events such as mitosis or deoxyribonucleic acid (DNA) repair and deacetylate nonhistone proteins involved in cell proliferation and death, altering their function. Histone deacetylase inhibitors (HDACi) constitute a promising treatment for cancer therapy due to their low toxicity. HDACi have been shown to induce differentiation, cell-cycle arrest, and apoptosis and to inhibit migration, invasion, and angiogenesis in many cancer cell lines. In addition, these compounds inhibit tumor growth in animal models and show antitumor activity in patients. HDACi alone and in combination with a variety of anticancer drugs are being tested in clinical trials, showing significant anticancer activity both in hematological and solid tumors. SAHA (vorinostat, Zolinza) was the first HDACi approved by the US Food and Drug Administration to enter the clinical oncology market for treating cutaneous T-cell lymphoma (CTCL) and is being tested for other malignancies.Keywords
This publication has 29 references indexed in Scilit:
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Regulation of Tissue-Specific and Extracellular Matrix-Related Genes by a Class I Histone DeacetylaseMolecular Cell, 2005
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- The Sir2 Family of Protein DeacetylasesAnnual Review of Biochemistry, 2004
- Identification of Novel Isoform-Selective Inhibitors within Class I Histone DeacetylasesJournal of Pharmacology and Experimental Therapeutics, 2003
- Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genesNature Medicine, 2001
- A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylasesProceedings of the National Academy of Sciences, 1998
- Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.Journal of Biological Chemistry, 1990
- n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cellsNature, 1977